STOCK TITAN

Alvotech Participates in the Goldman Sachs Global Healthcare Conference in Miami

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, announced its participation in the Goldman Sachs 46th Global Healthcare Conference in Miami from June 9-11, 2025. The company's management team will conduct one-on-one meetings during the event. Chief Strategy Officer Dr. Balaji Prasad will participate in a fireside chat on June 11, 2025, at 8:00 am EDT. The session will be publicly accessible via webcast through Alvotech's investor relations website, with a replay available for 90 days following the event.
Alvotech (NASDAQ: ALVO), un'azienda biotecnologica globale specializzata nello sviluppo di medicinali biosimilari, ha annunciato la sua partecipazione alla 46ª Conferenza Globale sulla Sanità di Goldman Sachs a Miami, dal 9 all'11 giugno 2025. Il team di gestione della società terrà incontri individuali durante l'evento. Il Chief Strategy Officer, Dr. Balaji Prasad, parteciperà a una conversazione informale il 11 giugno 2025 alle 8:00 EDT. La sessione sarà accessibile al pubblico tramite webcast sul sito web delle relazioni con gli investitori di Alvotech, con una replica disponibile per 90 giorni dopo l'evento.
Alvotech (NASDAQ: ALVO), una empresa biotecnológica global centrada en el desarrollo de medicamentos biosimilares, anunció su participación en la 46ª Conferencia Global de Salud de Goldman Sachs en Miami del 9 al 11 de junio de 2025. El equipo directivo de la compañía realizará reuniones individuales durante el evento. El Director de Estrategia, Dr. Balaji Prasad, participará en una charla informal el 11 de junio de 2025 a las 8:00 am EDT. La sesión será accesible públicamente vía webcast a través del sitio web de relaciones con inversores de Alvotech, con una repetición disponible durante 90 días después del evento.
글로벌 바이오테크 기업인 Alvotech(NASDAQ: ALVO)는 2025년 6월 9일부터 11일까지 마이애미에서 열리는 골드만 삭스 제46회 글로벌 헬스케어 컨퍼런스에 참가한다고 발표했습니다. 회사 경영진은 행사 기간 동안 일대일 미팅을 진행할 예정입니다. 전략 최고 책임자(Chief Strategy Officer)인 Dr. Balaji Prasad는 2025년 6월 11일 오전 8시(동부 표준시)에 진행되는 대화형 세션에 참여합니다. 이 세션은 Alvotech 투자자 관계 웹사이트를 통해 웹캐스트로 공개되며, 행사 후 90일 동안 다시보기 서비스가 제공됩니다.
Alvotech (NASDAQ : ALVO), une entreprise biotechnologique mondiale spécialisée dans le développement de médicaments biosimilaires, a annoncé sa participation à la 46e conférence mondiale sur la santé de Goldman Sachs à Miami, du 9 au 11 juin 2025. L'équipe de direction de la société tiendra des réunions individuelles lors de l'événement. Le directeur de la stratégie, Dr Balaji Prasad, participera à une discussion informelle le 11 juin 2025 à 8h00 EDT. La session sera accessible au public via un webcast sur le site des relations investisseurs d'Alvotech, avec une rediffusion disponible pendant 90 jours après l'événement.
Alvotech (NASDAQ: ALVO), ein globales Biotechnologieunternehmen, das sich auf die Entwicklung von Biosimilars spezialisiert hat, gab seine Teilnahme an der 46. Global Healthcare Conference von Goldman Sachs in Miami vom 9. bis 11. Juni 2025 bekannt. Das Management-Team des Unternehmens wird während der Veranstaltung Einzelgespräche führen. Chief Strategy Officer Dr. Balaji Prasad wird am 11. Juni 2025 um 8:00 Uhr EDT an einem Fireside Chat teilnehmen. Die Sitzung wird öffentlich per Webcast über die Investor-Relations-Website von Alvotech zugänglich sein, mit einer Wiedergabe, die 90 Tage nach der Veranstaltung verfügbar ist.
Positive
  • None.
Negative
  • None.

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Goldman Sachs 46th Global Healthcare Conference, which will be held in Miami, Florida June 9-11, 2025. Members of the management team will host one-on-one meetings at the conference. Dr. Balaji Prasad, Chief Strategy Officer, will participate in a fireside chat on Wednesday June 11, 2025, at 8:00 am EDT (12:00 GMT / 14:00 CEST).

A live webcast of the fireside chat will be available to the general public and can be accessed at https://investors.alvotech.com/events/event-details/goldman-sachs-46th-global-healthcare-conference-miami. After the event, a recording will be available for replay for 90 days.

About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech has launched two biosimilars. The current development pipeline includes biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy’s (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit www.alvotech.com.

Please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram, and YouTube.

ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS
Benedikt Stefansson, VP
alvotech.ir@alvotech.com


FAQ

When is Alvotech (ALVO) presenting at the Goldman Sachs Healthcare Conference 2025?

Alvotech will present at the Goldman Sachs Healthcare Conference on June 11, 2025, at 8:00 am EDT through a fireside chat with Chief Strategy Officer Dr. Balaji Prasad.

How can I watch Alvotech's (ALVO) presentation at the Goldman Sachs Healthcare Conference?

The presentation can be watched via live webcast at investors.alvotech.com/events, with a replay available for 90 days after the event.

Who will represent Alvotech (ALVO) at the Goldman Sachs Healthcare Conference 2025?

Dr. Balaji Prasad, Chief Strategy Officer, will represent Alvotech in a fireside chat, and the management team will host one-on-one meetings during the conference.

What dates is the Goldman Sachs Global Healthcare Conference 2025 being held?

The Goldman Sachs 46th Global Healthcare Conference will be held from June 9-11, 2025, in Miami, Florida.
Alvotech

NASDAQ:ALVO

ALVO Rankings

ALVO Latest News

ALVO Stock Data

3.36B
72.97M
64.88%
6.26%
0.17%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Luxembourg
Luxembourg